Original article Mean arterial pressure drop independent risk factor hepatorenal syndrome patients HBVACLF Xingrong Zhenga Yunwen Liana Peipei Wanga Lihua Zhenga Hewei Wua Jiaxin Lina Xiyao Chena Zhiliang Gaoabc Liang Penga Chan Xieabc Backgroundaims In patients acuteonchronic liver failure ACLF type 1 hepatorenal syndrome HRS critical organ failure complication resulted rapid mortality There efficient parameters predict HRS hepatitis B virus HBVrelated ACLF To assess HBVACLF risk factors evaluate association mean arterial pressures MAP HRS survival patients HBVACLF Methods A total 420 ACLF patients screened June 2015 June 2016 57 HBVACLF patients included study Clinical data MAP measurements patients collected Multivariate analyses Cox proportional hazards regression receiver operator characteristic ROC curves analyze Results In 30day study period 43 7544 patients survived Patients HRS group older higher Model EndStage Liver Disease MELD scores patients nonHRS group A MAP drop 95 mmHg independent predictor HRS sensitivity specificity 9286 6977 respectively The baseline MELD score independent risk factor HRS MAP drop OR 1582 P 0000 prothrombin time HRS MELD FIB independent prognostic factors 30day mortality The area ROC curve MAP drop 0808 P 0001 Conclusion A decrease MAP valuable predictor HRS patients HBVrelated ACLF MAP drop 95 mmHg useful predicting patient prognosis exploring new treatment measures patients HBVrelated ACLF Eur J Gastroenterol Hepatol 34 576584 Copyright 2022 The Authors Published Wolters Kluwer Health Inc Introduction Acuteonchronic liver failure ACLF characterized acute hepatic abnormalities result accumulating liver insults patients underlying chronic hepati tis liver cirrhosis 1 When liver function fails extrahepatic organs develop different functional disorders 2 Specific organ dysfunctions acute kidney injury AKI associated poor prognosis 2 necessitate liver transplantation 3 Due high mortality rate ACLF 1 determining urgency liver transplantation crucial 34 European Journal Gastroenterology Hepatology 2022 34576584 Keywords acuteonchronic liver failure cirrhosis mean arterial pressure drop prognosis type 1 hepatorenal syndrome aDepartment Infectious DiseasesThe Third Affiliated Hospital Sun YatSen University bKey Laboratory Tropical Disease Control Ministry Education Sun Yatsen University cGuangdong Provincial Key Laboratory Liver Disease Guangzhou Guangdong Province China Correspondence Chan Xie PhD Department Infectious Diseases The Third Affiliated Hospital Sun YatSen University 600 TianHe Road Guangzhou 510630 Guangdong Province China Tel 86 20 8525 2371 fax 86 20 8525 2046 email xchanmailsysueducn Dr Xingrong Zheng Dr Yunwen Lian considered cofirst authors Received 1 June 2021 Accepted 30 July 2021 This open access article distributed terms Creative Commons AttributionNon CommercialNo Derivatives License 40 CCBY NCND permissible download share work provided properly cited The work changed way commercially permission journal Hepatorenal syndrome HRS called HRSAKI lifethreatening complication liver cirrhosis 56 HRS characterized functional renal failure central underfilling caused combination splanchnic arterial systemic peripheral vasodilation 7 inadequate cardiac output 57 Arterial dilation key pathogenic event HRS leading reduc tion effective blood volume homeostatic activation reninangiotensinaldosterone induc tion renal vasoconstriction sympathetic nervous 38 Several lines evidence suggest HRS associated parenchymal kidney damage HRS classified type I type II HRS I involves rapidly progressive renal failure poor shortterm prog nosis HRS II moderate stable renal failure median survival 6 months 36 The management HRS major challenge Liver transplantation ideal treatment organ short age limited window time transplants pose important inherent drawbacks 39 Therapies improve renal perfusion tested including vaso constrictors terlipressin noradrenaline dopamine midodrine addition albumin 23610 Unfortunately therapies demon strate survival benefit At present studies focus improve treatment patients HRS 2 61011 effort preventing occur rence HRS diagnosis HRS early subclinical stage Currently reliable biomarkers identify incidence HRS predict prognosis endstage 0954691X Copyright 2022 The Authors Published Wolters Kluwer Health Inc DOI 101097MEG0000000000002314 576 Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited liver disease Previous studies shown liver volume serum sodium levels serum creatinine concentration urine output high renin activity predict HRS patients alcoholic v cirrhosis 7 Montoliu et al age basal serum creatinine levels high ceruplasmin CP val ues independent predictors HRS study 263 patients 12 In study HRS reported 55 patients 07 increase renal resistance index baseline 12 While current biomarker studies performed alcoholic liver disease Creatinine main component previous HRS predict models affected factors associated creatinine genera tion excretion 13 delayed insensitive bio marker renal function kidney injury 14 Other biomarkers primarily reflect severity chronic liver disease difficult followup observe clinically effectively clinical evaluation In clinical practice mean arterial pressure MAP reli able index dysfunction circulatory compensation patients liver cirrhosis ascites 8 A previous study revealed arterial blood pressure independently associated survival patients liver cirrhosis ascites period 1 year 15 Xu et al showed increasing MAP 65 mmHg normal level septic shock patients previous hypertension associated improved microcirculatory function characterized increased perfused vessel density higher proportion small perfused vessels 16 A recent study demonstrated hypertension history protective factor liveras sociated clinical decomposition mortality 17 Another study showed lower MAPs 5060 mmHg posi tively correlated higher morbidity kidney dysfunc tion cases 18 Low MAP closely associated hyperdynamic circulation seroperitoneum advance ment hepatorenal syndrome indicating optimal MAP important prognostic factor patients liver cirrhosis ascites 1518 In prospective cohort study longlasting impact baseline MAP levels progno sis patients hepatitis B virus HBVrelated cirrhosis ascites demonstrated 13 More specifically decrease MAP valuable predictor death patients HBVrelated liver cirrhosis ascites 13 Together stud ies indicate MAP useful determining prognosis exploring new treatment measures liver cirrhosis ascites 13 Although liver cirrhosis related HBVACLF MAP level maintained determine prognosis HBVACLF patients remains unclear studies determined impact changes MAP HRS occurrence HBVACLF Therefore finding convenient noninvasive clin ically accessible indicator crucial clinicians correct judgments early conveniently We propose researchers focus preventing occurrence HRS gain time improving liver function main taining renal function We anticipate efforts reduce occurrence HRS reducing mortality extending patient survival Materials methods Study design This retrospective study medical records patients diagnosed ACLF Third wwweurojghcom 577 Affiliated Hospital Sun Yatsen University Guangzhou China June 2015 June 2016 Chronic hep atitis B CHBrelated ACLF patients aged 18 65 years gender included study The diagnoses CHB ACLF according guidelines CHB ACLF management outlined American Association Study Liver Diseases Asia Pacific Association Study Liver CHB diag nosed according following criteria presence hepatitis B surface antigen HBsAg 6 months includes measuring levels HBVDNA hepatitis B e antigen serum alanine aminotransferase ALT determine infectivity liver biopsy assess liver disease ACLF diagnosed according following criteria jaundice coagulopathy resulting liver insults patients underlying CHB liver cirrho sis serum total bilirubin TBIL 5 mgdL 85 µmolL prothrombin activity 40 international normal ized ratio 15 Exclusion criteria included infection hepatitis virus alcoholic liver disease drugin duced liver disease active gastrointestinal bleeding septic shock underlying renal disease carcinoma cardiac respiratory failure renal insufficiency history preg nancy liver transplantation history Diagnosis type 1 HRS determined criteria proposed International Ascites Club 4 1 low glomerular filtra tion rate indicated serum creatinine 133 umolL 24h creatinine clearance 40 mLmin 2 absence shock ongoing bacterial infection fluid losses treat ment nephrotoxic drugs 3 improvement renal function following diuretic withdrawal plasma volume expansion 4 proteinuria 500 mgday 5 ultrasonographic evidence renal parenchymal dis ease urinary tract obstruction 30days mortality defined number patients died 30 days hospitalization The research authorized clinical ethics committee Third Affiliated Hospital Sun Yatsen University Clinical laboratory assessment Clinical biochemical data routine examinations collected time inclusion Laboratory tests included analysis biochemical indexes liver func tion ALT gamma glutamyl transpeptidase albumin TBIL HBV related tests HBsAg HBV DNA titer liver imaging examination creatinine potassium sodium levels prothrombin time platelet count The blood pressure patients measured profes sionally trained healthcare workers patient quiet awake Blood pressure measured day admission hospital electronic sphy gmomanometer Omron HEM6200 Dalian China Measurements performed times day average measurements day analyses MAP measurement point calculated MAP 13 SBP 23 DBP Treatment All patients given liverprotecting agents adenosylmethoinine diammonium glycyrrhizinate phosphatidylcholine energy mixture During fol lowup patients ascites treated diuretics Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited Independent risk factor hepatorenal syndrome Zheng et al 578 European Journal Gastroenterology Hepatology May 2022 Volume 34 Number 5 followed 10 g albumin infusions daily plasma albumin 35 gL If plasma albumin 30 gL patients ascites 20 g albumin given patients daily All patients given antiviral therapy entecavir chronic hepatitis B 400 ml fresh plasma 2 days Statistical analyses The results expressed mean SD median range Comparisons groups performed Students ttest MannWhitney U test Fishers exact test A value P 005 sides considered significant The survival curves generated COX method compared logrank test Logistic analyses performed determine baseline predictors HRS A receiver operating characteristic ROC curve generated area curve calcu lated All statistical analyses performed SPSS 230 statistical package SPSS Inc Chicago Illinois USA R package R version 361 20190705 Results Baseline patient characteristics During study period June 2015 June 2016 total 420 ACLF patients admitted 3rd affil iated hospital Sunyat Sen University Of patients 335 patients included according including cri teria Totally 91were excluded based complicated primary diseases causes ACLF HBV infection Fig 1 In remaining 244 patients 187 patients excluded based severe complica tions related ACLF BP data incomplete In total 57 patients assessed eligibility Fig 1 Total 57 final identified HBVrelated ACLF patients divided HRS group n 14 nonHRS group n 43 The baseline clinical characteristics patients shown Table 1 The average age HRS patients 5321 1338 years male pre dominance 1214 8571 And nonHRS patients 4502 1174 years significantly younger patients HRS group P 0033 male predominance3743 8605 Model endstage liver disease MELD score albumin Fib blood urea nitrogen BUN values patients HRS group 3609 836 2909 941 mgl 117 039 gl 844 812 µmoll respectively nonHRS group 2764 587 3330 519 gl 150 052 gl 408 238 µmoll respectively parame ters significantly different groups In conclusion patients HRS group older higher MELD scores patients nonHRS group There difference viral load levels HRS nonHRS groups P 0233 patients HRS group received antiHBV treatment prior hospital admittance One patient nonHRS group received antiHBV therapy HBV DNA level detective level patient There difference cases HBsAg level groups P 0052 Table 1 The 30day mortality rates 57 20 HRS nonHRS groups respectively Fig 1 Flow diagram patients screening enrollment process Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited Table 1 Comparison baseline clinical characteristics patients Hepatorenal syndrome HRS nonHRS group wwweurojghcom 579 Parameters Age years WBC 109L Platelet 109L AST UL GGT UL ALP UL Albumin gL TBIL umolL BS mmolL HBV DNA HBsAg IUml PCT ngml Prothrombin time S Fibrinogen gL NA mmolL MAP mmHg K mmolL HCO3 mmolL MELD HGB gL BUN umoll Creatinine umoll Survival days Patients HRS n 43 4502 1174 719 285 10870 4626 45172 64927 75446 49306 13898 39116 3330 5596 37599 14975 5296 220 35log7 614 log7 991176 1768097 1046 115 3069 936 150 052 13558 585 8748 1141 371 0 048 2346 342 2764 589 11226 2632 408 238 7474 2041 2888 266 Patients HRS n 14 5321 1338 785 235 9857 4770 24179 16337 6179 3591 12579 4269 2909 941 47358 20289 639 305 136 log7 452 log7 278475 267987 230 439 3402 964 117 039 13200 859 8912 1119 404 102 2190 387 3609 836 10250 2013 844 812 10263 2939 1786 1120 P Value 0033 0445 0483 0058 0344 0288 0038 0058 0147 0233 0022 0369 0256 0032 0083 0641 0251 0160 0000 0210 0000 0004 0030 ALP alkaline phosphate AST aspartate amiotransferase BS blood sugar BUN blood urea nitrogen GGT gamma glutamyl transpeptidase HBsAg hepatitis B surface antigen HBV DNA hepatitis B virus DNA HCO3 plasma bicarbonate concentration HGB hemoglobin K potassium MAP mean artery pressure MELD model endstage liver disease NA natrium sodium PCT plateletocrit TBIL total bilirubin WBC white blood cell count Analysis baseline variables predicting hepatorenal syndrome To assess association baseline variables HRS following parameters tested logistic regression analyses age albumin Fib MELD score BUN These variables showed significant differences HRS nonHRS groups Creatinine logistic regression MELD score calculated cre atinine values We MELD score asso ciated significantly increased risk HRS odds ratio OR 1182 95 confidence interval CI 10671309 Analysis baseline variables predicting survival All patients divided survival nonsurvival groups data collected 30 days calculate inhospital mortality rate Prothrombin time Fib MELD score significantly different survival nonsurvival groups Table 2 Eight patients diagnosed HRS nonsurvival group seven patients HRS died followup period There significant difference HRS diagnosis sur vival nonsurvival groupsX2 9095 P 0003 To assess baseline variables predict survival following parameters tested forward stepwise Cox proportional hazards regression analysis pro thrombin time Fib MELD score HRS diagnosis We prothrombin time HRS MELD Fib independently predicted 30day survival HBVACLF patients Table 3 Mean arterial pressures falls hepatorenal syndrome development Although baseline MELD score predicted HRS HBVACLF patients unclear patients developed HRS treatment prevent HRS occurrence As baseline MAP different HRS nonHRS groups collected MAP measurements course hospital stay We MAPs dropped 1202 298 mmHg HRS diagnosis In contrast MAPs dropped 789 380 mmHg nonHRS patients inhospital period P 005 Fig 2 In HRS group MAPdrop lasted 379 1528 days nonHRS group MAPdrop lasted 158 0932 days P 001 For 14 patients HRS group average time MAP drop HRS happen 536 1865 days Mean arterial pressures drop independent risk factor hepatorenal syndrome development hepatitis B virus acuteonchronic liver failure patients To evaluate drop MAP predict HRS ROC curve constructed MAP drop good predictor HRS patients HBVALCF AUROCs 0808 Creatinine level BUN MELD markers HRS patients HBVALCF AUROCs070 080 Fig 3 However creatinine BUN predict HRS prior occurrence MELD corrected rapidly As MAP pre dictive HRS improved relatively short time went determine specificity sensitivity positive predictive value PPV negative predictive value NPV positive likelihood ratio LR negative like lihood ratio LR different cutoff MAP drop values We cutoff MAP drop value 95 mmHg predicted risk HRS patients HBVACLF sensitivity specificity PPV NPV LR LR 9286 6977 500 9677 010 307 respectively Table 4 Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited Independent risk factor hepatorenal syndrome Zheng et al 580 European Journal Gastroenterology Hepatology May 2022 Volume 34 Number 5 Table 2 Comparison baseline clinical characteristics patients survival non survival group Parameters Patients survival n 43 Patients non survival n 14 P Value Age years WBC 109L Platelet 109L AST UL GGT UL ALP UL Albumin gL TBIL umolL BS mmolL HBV DNA HBsAg IUml PCT ngml Prothrombin time S Fibrinogen gL NA mmolL MAP mmHg K mmolL HCO3 mmolL MELD HGB gL BUN umoll Creatinine umoll 4960 892 746 273 9320 4875 47253 78644 5313 3995 12873 5339 3106 922 43486 20778 555 859 340lg7 647lg7 1137206 2121059 182 4038 3979 1047 108 044 13346 868 8734 946 415 087 2248 475 3517 728 10827 2692 742 859 8026 2626 4612 1359 732 276 11086 4521 37431 48769 7886 4716 13824 3453 3270 552 38750 15209 435 195 285lg7 565lg7 677023 1283634 117 129 2855 711 155 048 13515 594 8808 1196 366 052 2329 308 2777 2777 11043 2477 435 195 857 2429 0361 0860 0209 0575 0065 0435 0417 0353 0972 0753 0352 0439 0001 0002 0410 0829 0056 0456 0001 0778 0000 0482 ALP alkaline phosphate AST aspartate amiotransferase BS blood sugar BUN blood urea nitrogen GGT gamma glutamyl transpeptidase HBsAg hepatitis B surface antigen HBV DNA hepatitis B virus DNA HCO3 plasma bicarbonate concentration HGB hemoglobin K potassium MAP mean artery pressure MELD model endstage liver disease NA natrium sodium PCT plateletocrit TBIL total bilirubin WBC white blood cell count Table 3 Cox regression analyses baseline variables predicting survival EXPB 95 confidence interval FIB Prothrombin time MELD HRS βcoefficient 2230 0085 0120 1787 Z 3027 3775 3618 3419 P value 0002 0000 0000 0000 ExpB 0107 1088 1128 5973 Low 0025 1042 1057 2144 Up 0455 1137 1204 16638 FIB fibrinogen HRS Hepatorenal syndrome MELD model endstage liver disease PT prothrombin time Mean arterial pressures drop independent risk factor 30day mortality hepatitis B virus acuteonchronic liver failure patients Next performed forward stepwise Cox proportional hazards regression analysis patients MAP drop OR 1582 95 CI 13171900 P 0000 predict 30day mortality Discussion The present study demonstrated patients devel oped HRS older greater drops MAP higher MELD scores HRS P 005 A MAP drop 95 mmHg important independent predictor HRS HBVACLF patients The results retrospective study suggest reversal MAP effective tolerated preventive meas ures type 1 HRS HBVACLF patients This study provides new insight role circulation dys function development HRS HBVACLF ACLF develops acute decompensation cirrhosis defined hepatic extrahepatic organ fail ure 23 ACLF characterized high mortality ranging 23 74 12 In critically ill patients severe complications ACLF HRS hepatic encephalopathy hepatopulmonary syndrome spontane ous bacterial peritonitis associated poor quality life short survival 1319 This study eval uated drop MAP predictor HRS severe complication ACLF HRS occurs 2550 patients cirrhosis admitted hospital episode acute decompensation 20 HRS strong predictor poor survival short long term 2 Hospitalized cirrhotic patients HRS sur vive admission demonstrate1 12month mortality rates 58 63 respectively In study 5714 HRS patients 814 died 30day observation period hospital In contrast 30day mortality rate ACLF patients HRS 1395 643 Thus preventing HRS signifi cantly improve survival ACLF patients There new parameters traditional biomarkers predict HRS Urinary sodium excretion common indicator HRS 47 sodium excretion affected factors diu retic administration Other biomarkers associated HRS include serum cystatin C urinary serum neu trophil gelatinaseassociated lipocalin NGAL urinary IL18 kidney injury molecule 1 livertype fatty acidbind ing protein insulinlike growth factor tissue inhibitor metalloproteinase 21 These novel biomarkers increase Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited wwweurojghcom 581 Fig 2 Distribution mean artery pressure MAP drops different groups patients b Hepatorenal syndrome HRS group c nonHRS group severity liver injury predictive outcomes In addition urinary infection prevalent patients ACLF increase urinary biomarker excretion Therefore study required develop efficient controllable biomarkers aid diagnosing HRS early improve clinical outcomes In study analyzed clinical markers Fib prothrombin time MELD score albumin BUN significantly different HRS nonHRS groups Interestingly MELD score predictor HRS These results similar previous study patients poor liver condition severe ACLF develop complications including HRS 1581322 More importantly parameters corrected rapidly limits treatment potential patients suspected risk developing HRS Based effect MAP reflecting circulation vol ume improved short time consider interesting factor look Then compared baseline MAP groups significant difference predictive ability HRS However discovered HRS patients suffered MAP drop prior HRS occurrence Using ROC curve analysis selected cutoff MAP drop 95 mmHg predict HRS ACLF patients evidence severe cardiovascular dysfunction They increased decreased cardiac output 346 Increased cardiac output com pensation period performance developed decreased cardiac output result renal hypop erfusion ischemia 34913 A significant change patients cirrhosis portal hypertension accel erates release generation endogenous vasodi lators visceral blood circulation The release vasodilators results splanchnic vasodilatation blood volume expansion increased mesenteric blood flow 31322 Finally total effective arterial blood volume decreases leads systemic circulatory dysfunction Renal perfusion affected organs 213 Studies arterial hypertension patients cirrhosis shown prevalence hypertension reduced 23 high arterial blood pressure beneficial predictive factor hepatic decompensation liver dis easeassociated death 1517 The vasodilatory compli cations hepatorenal syndrome hepatopulmonary syndrome prevented patients high arterial blood pressure 13 MAP regarded perfusion pressure required maintaining blood flow organs considered important hemodynamic meas ure function circulation 13 MAP determining factor maintaining cerebral renal blood flow 1618 A previous study revealed arterial blood pressure independently associated survival patients liver cirrhosis ascites period 1 year 15 Another study reported baseline MAP independent correlative factor 5year mortality patients HBVrelated liver cirrhosis ascites 13 Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited Independent risk factor hepatorenal syndrome Zheng et al 582 European Journal Gastroenterology Hepatology May 2022 Volume 34 Number 5 Fig 3 Area receiveroperating characteristic ROC curves different variables predicting Hepatorenal syndrome HRS patients hep atitis B virus Acuteonchronic liver failure HBVALCF Mean artery pressure MAP drop model endstage liver disease MELD scores b blood urea nitrogen BUN c fibrinogen FIB d albumin e Moreover metaanalysis suggested use ter lipressin noradrenaline improves MAP results higher urine output reversal types HRS 11 These results indicate HRS occurred hemodynamic renal function disorders develop Therefore preventing correcting preclinical HRS valuable treating HRS Our results revealed MAP decrease 95 mmHg notable predictor HRS occurrence patients HBVACLF Like baseline MELD score1 MAP drop proved independent cor relative factor 30day mortality hospital stays The AUROC values greater 08 indicating satisfactory predictive ability MAP drop consistent independent predictors HRS patients Therefore MAP monitored drops optimal predictor HRS patients HBV ACLF In addition changes MAP indicative treat ment efficacy albumin vasoconstrictors improve blood pressure Our study number limitations First calculate sample size priori For retrospect study clinical data incomplete The relatively low number patients included study necessitates validation results larger cohorts Our study included hospital limiting external generalizabil ity results The use cardiac output monitoring central venous pressure values aid volume assessment study Thus direct indicator effective circulating blood Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited Table 4 Different cutoff mean artery pressure drop values evaluate risk Hepatorenal syndrome patients Hepatitis B virusAcute onchronic liver failure MAP drop mmHg Specificity Sensitivity NPV PPV LR LR wwweurojghcom 583 05 15 25 35 45 55 65 75 85 95 105 115 125 14 155 165 0047 0069 0093 0116 0163 0209 0372 0465 0605 0698 0744 0837 0907 0930 0953 1 1 1 1 1 1 1 0929 0929 0929 0929 0714 05 0286 0214 0143 0143 1 1 1 1 1 1 0941 0952 0963 0968 0889 0837 0796 0784 0774 0782 0255 0259 0264 0269 0280 0292 0325 0361 0433 0500 0476 0500 0500 0500 0500 1 0 0 0 0 0 0 0192 0154 0118 0102 0384 0597 0788 0845 0899 0857 1049 1075 1103 1132 1194 1265 1479 1736 2349 3071 279 3071 3071 3071 3071 NA Bold indicates MAP drop value ACLF Acuteonchronic liver failure HRS Hepatorenal syndrome LR positive likelihood ratio LR negative likelihood ratio MAP mean artery pressure NPV negative predictive value PPV positive predictive value volume Finally MAP drop cause conse quence renal dysfunction HBVACLF organ fail ure development understood Therefore additional studies addressing elevated MAP prevents HRS occurrence necessary require randomized trolled clinical design To end registered clinical study evaluate effect terlipressin prevention HRS improving mean arterial pressure NCT02489864 In conclusion important discovery ret rospective study MAP drop 95 mmHg important predictors HRS patients HBVACLF shortterm followup Our results extended predict patient prognosis explore new treatment measures directed optimizing treatment HBVACLF patients Acknowledgements This work supported grants Major National Science Technology Project prevention control major infectious diseases AIDS viral hepatitis 2018ZX 10302205002 The Ten FiveYear Plan fund Third Affiliated Hospital Sun Yatsen University SW201701 Guangzhou Science Technology Plan Projects 201904010442 Natural Science Foundation China 81472259 Study concept enrolled subjects CX XZ YL Data collection PW LZ Data analysis HW JL XC Writing original draft XZ YL Critical revision manuscript important intellec tual content ZG LP CX All authors approved final version manuscript Conflicts There conflicts References 1 Kumar R Krishnamoorthy TL Tan HK Lui HF Chow WC Change model endstage liver disease score weeks indicator mortality liver transplantation 60 days acuteonchronic liver failure Gastroenterol Rep Oxf 2015 3122127 2 Arora V Maiwall R Rajan V Jindal A Muralikrishna Shasthry S Kumar G et al Terlipressin superior noradrenaline management acute kidney injury acute chronic liver failure Hepatology 2020 71600610 3 Gifford FJ Morling JR Fallowfield JA Systematic review metaanalysis vasoactive drugs treatment hepatorenal syn drome type 1 Aliment Pharmacol Ther 2017 45593603 4 Zhang J Rössle M Zhou X Deng J Liu L Qi X Terlipressin treatment hepatorenal syndrome overview current evidence Curr Med Res Opin 2019 35859868 5 Boyer TD Sanyal AJ GarciaTsao G Blei A Carl D Bexon AS Teuber P Terlipressin Study Group Predictors response terlipressin plus albumin hepatorenal syndrome HRS type 1 relationship serum creatinine hemodynamics J Hepatol 2011 55315321 6 Salerno F Navickis RJ Wilkes MM Albumin treatment regimen type 1 hepatorenal syndrome doseresponse metaanalysis BMC Gastroenterol 2015 15167 7 Ghosh S Choudhary NS Sharma AK Singh B Kumar P Agarwal R et al Noradrenaline vs terlipressin treatment type 2 hepatorenal syndrome randomized pilot study Liver Int 2013 3311871193 8 Kalambokis GN Tsiakas I Christaki M Koustousi C Christou L Baltayiannis G Christodoulou D Systemic hemodynamic response terlipressin predicts development hepatorenal syndrome survival advanced cirrhosis Eur J Gastroenterol Hepatol 2018 30659667 9 Maddukuri G Cai CX Munigala S Mohammadi F Zhang Z Targeting early substantial increase mean arterial pressure critical management type 1 hepatorenal syndrome combined retro spective pilot study Dig Dis Sci 2014 59471481 10 Boyer TD Sanyal AJ Wong F Todd Frederick R Lake JR OLeary JG et al Terlipressin plus albumin effective albumin improving renal function patients cirrhosis hepatorenal syndrome type 1 Gastroenterology 2016 15015791589e1572 11 Sridharan K Sivaramakrishnan G Vasoactive agents hepatorenal syndrome mixed treatment comparison network metaanalysis trial sequential analysis randomized clinical trials J Gen Intern Med 2018 3397102 12 Planas R Montoliu S Ballesté B Rivera M Miquel M Masnou H et al Natural history patients hospitalized management cirrhotic ascites Clin Gastroenterol Hepatol 2006 413851394 13 Li H Guo Z Yang X Sun D Mean arterial pressure drop inde pendent risk factor death patients HBVrelated cirrhosis ascites Turk J Gastroenterol 2017 282630 14 LisowskaMyjak B Serum urinary biomarkers acute kidney injury Blood Purif 2010 29357365 15 Llach J Ginès P Arroyo V Rimola A Titó L Badalamenti S et al Prognostic value arterial pressure endogenous vasoactive systems renal function cirrhotic patients admitted hospital treatment ascites Gastroenterology 1988 94482487 16 Xu JY Ma SQ Pan C He HL Cai SX Hu SL et al A high mean arterial pressure target associated improved microcirculation septic shock patients previous hypertension prospective open label study Crit Care 2015 19130 Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited Independent risk factor hepatorenal syndrome Zheng et al 584 European Journal Gastroenterology Hepatology May 2022 Volume 34 Number 5 17 Gomez EV Rodriguez YS Bertot LC Gonzalez AT Perez YM Soler EA et al The natural history compensated HCVrelated cirrhosis prospective longterm study J Hepatol 2013 58434444 18 Thooft A Favory R Salgado DR Taccone FS Donadello K De Backer D et al Effects changes arterial pressure organ perfusion septic shock Crit Care 2011 15R222 19 Moore CM Van Thiel DH Cirrhotic ascites review pathophysiology diagnosis management World J Hepatol 2013 5251263 20 Davenport A Sheikh MF Lamb E Agarwal B Jalan R Acute kidney injury acuteonchronic liver failure hepatorenal syn drome fit Kidney Int 2017 9210581070 21 AA Q SE F E H et al Urinary biomarkers acute kidney injury patients liver cirrhosis ISRN Nephrol 2014 2014 376795 22 Sanyal AJ Boyer TD Frederick RT Wong F Rossaro L Araya V et al Reversal hepatorenal syndrome type 1 terlipressin plus albumin vs placebo plus albumin pooled analysis OT0401 REVERSE randomised clinical studies Aliment Pharmacol Ther 2017 4513901402 23 Henriksen JH Fuglsang S Bendtsen F Møller S Arterial hypertension cirrhosis arterial compliance volume distribution central hae modynamics Gut 2006 55380387 Copyright 2022 Wolters Kluwer Health Inc Unauthorized reproduction article prohibited